Cancer Family
Female Reproductive System Adnexal Neoplasm
CI-CAN-00000180Explore in graph →
Non-malignant765 active trials5 approved drugs94 evidence items
- NCIt
- C212117
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000180Explore in graph →
Clinical trials
3,476 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01809379 | Intraperitoneal Aerosol High-pressure Chemotherapy for Women With Recurrent Ovarian Cancer | completed | Phase 2 | 69 | Ruhr University of BochumOTHER | 1 | Jul 8, 2022 | clinicaltrials |
| NCT03562897 | Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer | completed | Phase 2 | 40 | Catalysis SLINDUSTRY | 1 | Jul 6, 2022 | clinicaltrials |
| Phase 2 Study of OTL38 for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer |
| completed |
| Phase 2 |
| 48 |
| On Target Laboratories, LLCINDUSTRY |
| 1 |
| Jun 21, 2022 |
| clinicaltrials |
| NCT02736305 | Use of Regorafenib in Recurrent Epithelial Ovarian Cancer | completed | Phase 2 | 21 | National Cancer Centre, SingaporeOTHER | 1 | Jun 13, 2022 | clinicaltrials |
| NCT03365791 | PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies | completed | Phase 2 | 76 | Novartis PharmaceuticalsINDUSTRY | 1 | May 27, 2022 | clinicaltrials |
| NCT00432094 | Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors | completed | Phase 2 | 23 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | May 17, 2022 | clinicaltrials |
| NCT02107937 | Phase II Study DCVAC/OvCa Added to First Line Carboplatin and Paclitaxel Newly Diagnosed Epithelial Ovarian Carcinoma | completed | Phase 2 | 136 | SOTIO a.s.INDUSTRY | 2 | May 4, 2022 | clinicaltrials |
| NCT00181701 | Intraperitoneal Paclitaxel and Carboplatin in the Treatment of Women With Carcinoma of Mullerian Origin | completed | Phase 2 | 46 | Massachusetts General HospitalOTHER | 0 | Apr 14, 2022 | clinicaltrials |
| NCT02983799 | Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status | completed | Phase 2 | 272 | AstraZenecaINDUSTRY | 2 | Apr 13, 2022 | clinicaltrials |
| NCT00853307 | MLN8237 for Treatment of Participants With Ovarian, Fallopian Tube, or Peritoneal Carcinoma | completed | Phase 2 | 31 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 8, 2022 | clinicaltrials |
| NCT02674061 | Efficacy and Safety Study of Pembrolizumab (MK-3475) in Participants With Advanced Recurrent Ovarian Cancer (MK-3475-100/KEYNOTE-100) | completed | Phase 2 | 376 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Mar 24, 2022 | clinicaltrials |
| NCT02608684 | A Study of Pembrolizumab With Standard Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer(PemCiGem) | completed | Phase 2 | 21 | Cedars-Sinai Medical CenterOTHER | 1 | Mar 23, 2022 | clinicaltrials |
| NCT02889900 | Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer(CONCERTO) | completed | Phase 2 | 62 | AstraZenecaINDUSTRY | 1 | Mar 8, 2022 | clinicaltrials |
| NCT02178722 | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | completed | Phase 1 / Phase 2 | 444 | Incyte CorporationINDUSTRY | 1 | Feb 14, 2022 | clinicaltrials |
| NCT00096200 | Sorafenib With or Without Paclitaxel and Carboplatin in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | completed | Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | Feb 8, 2022 | clinicaltrials |
| NCT00317772 | Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer | completed | Phase 1 / Phase 2 | 19 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 7, 2022 | clinicaltrials |
| NCT00886691 | Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 2 | 150 | GOG FoundationNETWORK | 1 | Feb 4, 2022 | clinicaltrials |
| NCT02764333 | TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer | completed | Phase 2 | 29 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 30, 2021 | clinicaltrials |
| NCT02657928 | Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer | completed | Phase 2 | 40 | Mayo ClinicOTHER | 1 | Oct 26, 2021 | clinicaltrials |
| NCT00888615 | Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 2 | 58 | GOG FoundationNETWORK | 1 | Oct 20, 2021 | clinicaltrials |
| NCT01720173 | Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer | completed | Phase 2 | 30 | Gynecologic Oncology GroupNETWORK | 1 | Oct 20, 2021 | clinicaltrials |
| NCT01551745 | Salvage Ovarian FANG™ Vaccine + Bevacizumab | completed | Phase 2 | 5 | Gradalis, Inc.INDUSTRY | 1 | Oct 19, 2021 | clinicaltrials |
| NCT01853644 | Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer(TIVO) | completed | Phase 2 | 31 | Northwestern UniversityOTHER | 1 | Oct 12, 2021 | clinicaltrials |
| NCT02853318 | Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 40 | Roswell Park Cancer InstituteOTHER | 1 | Oct 6, 2021 | clinicaltrials |
| NCT03685695 | Physical Activity Monitored by Fitbit Charge 2 in Improving Quality of Life in Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 2 | 9 | Roswell Park Cancer InstituteOTHER | 1 | Sep 2, 2021 | clinicaltrials |
| NCT02993705 | Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS)(MITO 26) | completed | Phase 2 | 45 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Aug 25, 2021 | clinicaltrials |
| NCT01631552 | Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer | completed | Phase 1 / Phase 2 | 515 | Gilead SciencesINDUSTRY | 1 | Aug 12, 2021 | clinicaltrials |
| NCT03394885 | Atezolizumab With Neoadjuvant Chemotherapy for Patients With Newly-Diagnosed Advanced-Stage Ovarian Cancer(AdORN) | completed | Phase 1 / Phase 2 | 18 | Duke UniversityOTHER | 1 | Aug 12, 2021 | clinicaltrials |
| NCT00574678 | Analyzing the Composition of Tears to Identify Cancer(ACT) | completed | Phase 1 / Phase 2 | 150 | University of ArkansasOTHER | 1 | Aug 5, 2021 | clinicaltrials |
| NCT00806156 | Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Ovarian Cancer | completed | Phase 2 | 178 | Nektar TherapeuticsINDUSTRY | 3 | Jul 12, 2021 | clinicaltrials |
| NCT01770301 | Efficacy and Safety of Bevacizumab (Avastin®) Combined to Weekly Paclitaxel Followed by Bevacizumab (Avastin®) Alone in Patients With Relapsed Ovarian Sex-cord Stromal Tumours (ALIENOR)(ALIENOR) | completed | Phase 2 | 60 | ARCAGY/ GINECO GROUPOTHER | 1 | Jul 2, 2021 | clinicaltrials |
| NCT00325351 | ZK-Epo Given With Carboplatin in Patients With Recurrent Ovarian Cancer | completed | Phase 2 | 45 | BayerINDUSTRY | 2 | Apr 8, 2021 | clinicaltrials |
| NCT00945191 | Combination Chemotherapy With CS-1008 to Treat Ovarian Cancer | completed | Phase 2 | 24 | Daiichi SankyoINDUSTRY | 1 | Apr 8, 2021 | clinicaltrials |
| NCT03901118 | Chiauranib in Combination With Chemotherapy in Patients With Ovarian Cancer | completed | Phase 2 | 47 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | Mar 19, 2021 | clinicaltrials |
| NCT02249013 | Short-course HIPEC in Advanced Epithelial Ovarian Cancer | completed | Phase 2 | 15 | Professor Fernando Figueira Integral Medicine InstituteOTHER | 0 | Mar 18, 2021 | clinicaltrials |
| NCT01037790 | Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer | completed | Phase 2 | 304 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 11, 2021 | clinicaltrials |
| NCT01610206 | A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer | completed | Phase 2 | 148 | Linda R DuskaOTHER | 1 | Feb 25, 2021 | clinicaltrials |
| NCT01989546 | Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations | completed | Phase 1 / Phase 2 | 9 | National Cancer Institute (NCI)NIH | 1 | Feb 23, 2021 | clinicaltrials |
| NCT01146795 | Neoadjuvant Therapy for Ovarian Cancer | completed | Phase 2 | 32 | Jason D. WrightOTHER | 1 | Feb 9, 2021 | clinicaltrials |
| NCT02022917 | Postoperative Adjuvant Chemotherapy With Bevacizumab and Maintenance Bevacizumab After Neoadjuvant Chemotherapy for Ovarian Cancer | completed | Phase 2 | 22 | Chang Gung Memorial HospitalOTHER | 1 | Jan 27, 2021 | clinicaltrials |
| NCT02725489 | Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers | completed | Phase 2 | 13 | Mary Crowley Medical Research CenterOTHER | 1 | Jan 27, 2021 | clinicaltrials |
| NCT03742713 | Efficacy Study of CPC634 (CriPec® Docetaxel) in Platinum Resistant Ovarian Cancer(CINOVA) | completed | Phase 2 | 25 | Cristal TherapeuticsINDUSTRY | 3 | Dec 28, 2020 | clinicaltrials |
| NCT00420381 | Evaluation of Enzastaurin in the Treatment of Persistent or Recurrent Ovarian or Primary Peritoneal Cancer | completed | Phase 2 | 28 | Eli Lilly and CompanyINDUSTRY | 1 | Dec 19, 2020 | clinicaltrials |
| NCT01519869 | Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma | completed | Phase 2 | 28 | Rachel MillerOTHER | 1 | Dec 14, 2020 | clinicaltrials |
| NCT02490488 | Masitinib in Combination With Gemcitabine in Advanced/Metastatic Epithelial Ovarian Cancer Patients | completed | Phase 2 / Phase 3 | 248 | AB ScienceINDUSTRY | 6 | Dec 8, 2020 | clinicaltrials |
| NCT00551070 | Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer | completed | Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | Dec 3, 2020 | clinicaltrials |
| NCT00227721 | Gemcitabine and Docetaxel in Treating Patients With Relapsed or Refractory Ovarian Epithelial or Peritoneal Cancer | completed | Phase 2 | 30 | Robert MorrisOTHER | 1 | Dec 2, 2020 | clinicaltrials |
| NCT02399592 | Tocotrienol as a Nutritional Supplement in Patients With Advanced Ovarian Cancer(Toco-Ovar) | completed | Phase 2 | 23 | Vejle HospitalOTHER | 1 | Nov 30, 2020 | clinicaltrials |
| NCT00436215 | Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer | completed | Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Nov 23, 2020 | clinicaltrials |
| NCT03480750 | Trial of Trientine Plus Pegylated Liposomal Doxorubicin and Carboplatin in Epithelial Ovarian Cancer(Trientine) | completed | Phase 1 / Phase 2 | 18 | National Cheng-Kung University HospitalOTHER | 0 | Nov 10, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Jul 8, 2022source: clinicaltrials